China Medical System Holdings (HK:0867) has released an update.
China Medical System Holdings Limited reported a downturn in its interim financial results for the first half of 2024, with a turnover decrease of 21.7% and a profit reduction of 52.8% from the previous year. Despite these challenges, the company saw an improvement compared to the second half of 2023, suggesting adaptation to the impacts of National Volume Based Procurement and a shift towards growth driven by non-national VBP exclusive and innovative products. The company also highlighted the entry of four innovative drugs into large-scale clinical applications and the approval of a new drug that improves colonoscopy diagnosis sensitivity.
For further insights into HK:0867 stock, check out TipRanks’ Stock Analysis page.
